UroGen Pharma Ltd. (URGN): Long-Term Debt

Annual figures by period end, from SEC filings.

$125.00M

As of 2025-12-31

$200.00M

As of 2026-06-30

Period ended	Long-Term Debt	Change YoY	Source filing
2025-12-31	$125.00M	n/a	2026-03-02, Balance as of period end

Long-Term Debt at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Long-Term Debt	Change YoY
UroGen Pharma Ltd. (URGN)	2025-12-31	$125.00M	n/a
Zevra Therapeutics, Inc. (ZVRA)	2025-12-31	$61.93M	+4.1%
Lifecore Biomedical, Inc. (LFCR)	2025-05-25	$130.44M	+4.6%
Cytokinetics Inc (CYTK)	2024-12-31	$619.52M	-3.1%
Standard Biotools Inc. (LAB)	2024-12-31	$299.0K	-99.5%
ARS Pharmaceuticals, Inc. (SPRY)	2025-12-31	$96.37M	n/a
Eton Pharmaceuticals, Inc. (ETON)	2024-12-31	$29.81M	n/a
Phathom Pharmaceuticals, Inc. (PHAT)	2025-12-31	$209.09M	+3.8%
Kura Oncology, Inc. (KURA)	2025-12-31	$9.70M	+1.9%

Compare URGN, ZVRA, LFCR, CYTK side by side · Screen every company in Pharmaceutical Preparations ↗